Table 1

Demographic and clinical characteristics of the overall study population, stratified by sex; pooled data from OPAL Broaden and OPAL Beyond

VariableAll treatment groups
Sex, N (%)Male: 373 (45.7)Female: 443 (54.3)
Age (years), mean (SD)48.0 (12.1)49.6 (12.1)
Race, white, n (%)351 (94.1)421 (95.0)
BMI (kg/m2), mean (SD)29.5 (5.1)29.8 (6.7)
PsA duration
 <2 years88 (23.6)86 (19.4)
 ≥2 years285 (76.4)357 (80.6)
SJC (66), mean (SD)11.0 (9.0)12.2 (9.8)
TJC (68), mean (SD)19.4 (13.8)22.0 (14.4)*
SPARCC, patients included†
 n (%)290 (77.7)337 (76.1)
 Mean (SD)4.7 (3.5)6.1 (3.9)***
LEI, patients included‡
 n (%)245 (65.7)310 (70.0)
 Mean (SD)2.6 (1.6)3.0 (1.6)*
DSS, patients included§
 n (%)218 (58.4)213 (48.1)*
 Mean (SD)8.9 (7.9)8.1 (8.3)
 CRP (mg/L), mean (SD)14.6 (26.1)10.2 (16.2)*
PASI, patients included¶
 n (%)273 (73.2)285 (64.3)
 Mean (SD)11.4 (9.6)8.3 (7.3)***
PGA-PsA (VAS in mm), mean (SD)61.3 (22.6) (N=372)64.2 (22.5)
PGA-PsO**, n (%)
 011 (2.9)20 (4.5)
 1100 (26.8)136 (30.7)
 2154 (41.3)190 (42.9)
 392 (24.7)80 (18.1)
 414 (3.8)14 (3.2)
HAQ-DI, mean (SD)1.1 (0.6) (N=372)1.3 (0.7)***
SF-36 PCS, mean (SD)35.4 (8.9) (N=370)34.1 (8.2)* (N=442)
SF-36 MCS, mean (SD)42.3 (11.8) (N=370)38.9 (11.7)*** (N=442)
FACIT-F, mean (SD)30.2 (10.7) (N=372)25.5 (10.7)***
Patient Global Assessment of Arthritis and Skin (VAS in mm), mean (SD)53.6 (19.9) (N=371)54.1 (20.3) (N=436)
Patient Assessment of Arthritis Pain (VAS in mm), mean (SD)53.9 (23.7) (N=371)56.2 (22.8)
Presence of depression††, yes, n (%)21 (5.6)67 (15.1)***
  • *p<0.05, **p<0.001, ***p<0.0001 for females versus males.

  • †Patients with baseline SPARCC >0.

  • ‡Patients with baseline LEI >0.

  • §Patients with baseline DSS >0.

  • ¶PASI was assessed in patients with baseline BSA ≥3% and PASI >0.

  • **PGA-PsO assessed in patients with baseline PGA-PsO >0.

  • ††Ascertained from medical history.

  • BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; DSS, Dactylitis Severity Score; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability Index; LEI, Leeds Enthesitis Index; n, number of patients with demographic/clinical characteristic at baseline; N, number of evaluable patients; PASI, Psoriasis Area and Severity Index; PGA-PsA, Physician Global Assessment of PsA; PGA-PsO, Physician Global Assessment of Psoriasis; PsA, psoriatic arthritis; SF-36 PCS, Short Form-36 Physical Component Summary; SJC, swollen joint count; SPARCC, Spondyloarthritis Research Consortium of Canada; TJC, tender joint count; VAS, Visual Analogue Scale.